Entrada Therapeutics Holds Virtual Annual Stockholders Meeting

Entrada Therapeutics Inc ( (TRDA) ) has issued an announcement.

On June 11, 2025, Entrada Therapeutics, Inc. held its Annual Meeting of Stockholders virtually, where a quorum was established with 30,259,526 shares represented. During the meeting, stockholders elected three Class I directors to the Board and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (TRDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.

Spark’s Take on TRDA Stock

According to Spark, TipRanks’ AI Analyst, TRDA is a Neutral.

The overall stock score for Entrada Therapeutics Inc. reflects its robust financial performance and attractive valuation, despite recent challenges in sustaining revenue growth. Technical indicators suggest caution, as the stock shows a bearish trend. Positive corporate developments, such as strategic board appointments and regulatory approvals, bolster the company’s potential.

To see Spark’s full report on TRDA stock, click here.

More about Entrada Therapeutics Inc

Entrada Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapeutics for the treatment of rare diseases. The company is engaged in creating novel therapeutics using its proprietary Endosomal Escape Vehicle (EEV) technology platform.

Average Trading Volume: 140,661

Technical Sentiment Signal: Sell

Current Market Cap: $313.5M

See more data about TRDA stock on TipRanks’ Stock Analysis page.